Head and Neck Cancer - Immunotherapy - ARID1A mutation

Association details:

Biomarker:	ARID1A mutation
Cancer:	Head and Neck Cancer
Drug Class:	Immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

AACR 2021

Title:

1641 - The predictive values of ARID1A mutations for response to immune checkpoint inhibitors are varied in different types of solid tumors

Published date:

03/10/2021

Excerpt:

Then we analyzed the associations between ARID1A mutations and OS after ICIs therapy….Moreover, the patients with head and neck cancer in the Mut group had longer median OS (28 vs 10 months, P = 0.0110)….But ARID1A mutations just showed the predictive values for ICIs therapy in head and neck cancer...